Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequence of the oligodeoxy nucleotide is TTYSGGAAWT, wherein Y is C or T; S is C or G; and W is A or T. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
January 7, 2020
Assignees:
JIANGSU KEYGEN BIOTECH CORP., LTD, NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD
Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequences of the oligodeoxy nucleotide is TTTCSCGCS, wherein S is C or G. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
October 15, 2019
Assignees:
JIANGSU KEYGEN BIOTECH CORP., LTD, NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD
Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequence of the oligodeoxy nucleotide is RGGGAHTTYCS, wherein R is G or A; H is A or C or T; Y is C or T; S is C or G. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
April 9, 2019
Assignees:
NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD, JIANGSU KEYGEN BIOTECH CORP., LTD